With 0.99 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.17 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $1.47 whereas the lowest price it dropped to was $1.34. The 52-week range on MYNZ shows that it touched its highest point at $22.40 and its lowest point at $1.37 during that stretch. It currently has a 1-year price target of $14.00. Beta for the stock currently stands at 0.26.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MYNZ was down-trending over the past week, with a drop of -8.86%, but this was down by -31.43% over a month. Three-month performance dropped to -66.12% while six-month performance fell -69.81%. The stock lost -66.67% in the past year, while it has lost -91.98% so far this year.
Float and Shares Shorts:
At present, 3.81 million MYNZ shares are outstanding with a float of 3.69 million shares on hand for trading. On 2025-05-30, short shares totaled 39353.0, which was 102.99999 higher than short shares on 1745971200. In addition to Mr. Guido Baechler as the firm’s CEO & Executive Director, Dr. Christopher Von Toerne P.M.P., Ph.D. serves as its Chief Operating Officer.
Institutional Ownership:
Through their ownership of 0.061339997 of MYNZ’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, MYNZ reported revenue of $214761.0 and operating income of -$6800018.0. The EBITDA in the recently reported quarter was -$5437012.0 and diluted EPS was $nan.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With MYNZ analysts setting a high price target of 14.0 and a low target of 14.0, the average target price over the next 12 months is 14.0. Based on these targets, MYNZ could surge 872.22% to reach the target high and rise by 872.22% to reach the target low. Reaching the average price target will result in a growth of 872.22% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$10.84 being high and -$10.84 being low. For MYNZ, this leads to a yearly average estimate of -$10.84.
